IOL Chemicals Standalone December 2022 Net Sales at Rs 523.48 crore, down 5.7% Y-o-Y
NULL08-02-2023
Q3FY23 Quarterly Result Announced for IOL Chemicals and Pharmaceuticals Ltd.
IOL Chemicals and Pharmaceuticals announced Q3FY23 results: Q3FY23: Total income stood at Rs 530 crore against Rs 546 crore QoQ and Rs 564 crore YoY EBITDA at Rs 50 crore as compared to Rs 37 crore QoQ and Rs 68 crore YoY Net profit of the company at Rs 24.15 crore against Rs 15.67 crore QoQ and Rs 40.07 crore YoY Paracetamol capacity expansion by 1,800 MTPA completed Company focusing on frugal manufacturing practices to reduce raw material costs and expand margins Commenting on the quarterly performance, Dr Sanjay Chaturvedi, Executive Director & CEO said, “The quarterly performance reflects our commitment to control our costs and improve our margin trajectory. For the third quarter, EBITDA and net profit margins – both improved sequentially. Apart from cost rationalisation, we have completed our capacity enhancement of Paracetamol by 1,800 MTPA to take total capacity to 3,600 MTPA with backward integration of Para Amino Phenol (PAP) and we expect this capacity enhancement to boost volume growth from next quarter onwards.” Result PDF08-02-2023
IOL CHEMICALS & PHARMACEUTICALS LTD. - 524164 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
IOL Chemicals and Pharmaceuticals Reports Q3 FY23 Results07-02-2023
IOL CHEMICALS & PHARMACEUTICALS LTD. - 524164 - Corporate Action-Board approves Dividend
We wish to inform you that the Board of Directors in its meeting held on today i.e. 7th February 2023 has inter alia considered and approved: Declared an Interim Dividend of Rs. 4/- (Rupees four only) per Equity Share of Face Value Rs.10/- each for the Financial Year 2022-23. Fixed 17th February 2023 (Friday) as the Record Date to determine the names of the equity shareholders, who shall be entitled to receive the above said Interim Dividend. The payment of the Interim Dividend shall be made to the eligible shareholders before 8th March 2023.07-02-2023
IOL CHEMICALS & PHARMACEUTICALS LTD. - 524164 - Board Meeting Outcome for Outcome Of The Board Meeting Dated 7Th February 2023 And Submission Of Audited Financial Results For The Quarter And Nine Months Ended 31St December 2022
Pursuant to Regulations 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and further to our letter dated 1st February 2023, we wish to inform you that the Board of Directors in its meeting held on today i.e. 7th February 2023 has inter alia considered and approved: 1. The Audited Financial Results (Standalone & Consolidated) for the quarter and nine months ended 31st December 2022. Copy of the said Financial Results along with unmodified Auditors Report thereon is enclosed herewith as 'Annexure - 1'. 2. Declared an Interim Dividend of Rs. 4/- (Rupees four only) per Equity Share of Face Value Rs.10/- each for the Financial Year 2022-23. 3. Fixed 17th February 2023 (Friday) as the Record Date to determine the names of the equity shareholders, who shall be entitled to receive the above said Interim Dividend. The payment of the Interim Dividend shall be made to the eligible shareholders before 8th March 2023.07-02-2023
IOL CHEMICALS & PHARMACEUTICALS LTD. - 524164 - Outcome Of The Board Meeting Dated 7Th February 2023 And Submission Of Audited Financial Results For The Quarter And Nine Months Ended 31St December 2022
Pursuant to Regulations 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and further to our letter dated 1st February 2023, we wish to inform you that the Board of Directors in its meeting held on today i.e. 7th February 2023 has inter alia considered and approved: 1. The Audited Financial Results (Standalone & Consolidated) for the quarter and nine months ended 31st December 2022. Copy of the said Financial Results along with unmodified Auditors Report thereon is enclosed herewith as 'Annexure - 1'. 2. Declared an Interim Dividend of Rs. 4/- (Rupees four only) per Equity Share of Face Value Rs.10/- each for the Financial Year 2022-23. 3. Fixed 17th February 2023 (Friday) as the Record Date to determine the names of the equity shareholders, who shall be entitled to receive the above said Interim Dividend. The payment of the Interim Dividend shall be made to the eligible shareholders before 8th March 2023.07-02-2023
IOL CHEMICALS & PHARMACEUTICALS LTD. - 524164 - Corporate Action-Board to consider Dividend
Board to consider Q3 results & Interim Dividend on Feb 07, 202301-02-2023
IOL CHEMICALS & PHARMACEUTICALS LTD. - 524164 - Corporate Action-Board to consider Dividend
Board to consider Q3 results & Interim Dividend on Feb 07, 202201-02-2023
IOL CHEMICALS & PHARMACEUTICALS LTD. - 524164 - Intimation Of Incorporation Of Wholly Owned Subsidiary
This is in continuation to our previous communication dated 15th November 2022 on the captioned subject. Pursuant to the Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that a wholly owned subsidiary of the Company by the name 'IOL GLOBAL LIMITED' has been Incorporated in UK under the Companies Act 2006 of the England and wales on 30th January 2022. The details as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/ CFD/CMD/4/ 2015 dated 9th September, 2015 are attached as an Annexure A to this letter.01-02-2023
IOL CHEMICALS & PHARMACEUTICALS LTD. - 524164 - Board Meeting Intimation for Notice Of The Board Meeting
IOL CHEMICALS & PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/02/2023 ,inter alia, to consider and approve In terms of Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the next meeting of the Board of Directors is scheduled to be held on Tuesday, the 7th February 2023 inter-alia to consider and approve the Audited Financial Results of the Company for the Quarter and nine months ended 31st December 2022 and declaration of Interim Dividend, if any, for the Financial Year 2022-2023. Further, pursuant to the requirements of SEBI (Prohibition of Insider Trading) Regulations, 2015 and Company''s "Code of Conduct to Regulate, Monitor and Reporting of Trading by Designated Persons", the Trading Window which is closed with effect from 01st January 2022 shall continue to close till the expiry of 48 hours from the date of financial results for Quarter and nine months ended 31st December 2022 are made public. Accordingly, the trading window shall reopen on the 10th February 2023.01-02-2023